The benign and orderly competition of pharmaceutical enterprises allows the public to use low-cost medicines and safe medicines, and the majority of the people benefit.
According to media reports, on September 24, under the guidance of the National Medical Insurance Bureau and other departments, the 25 provinces and the Xinjiang Production and Construction Corps, which participated in the procurement of pharmaceuticals, expanded their joint recruitment in Shanghai, resulting in the results of the proposed election. A total of 77 companies participated in the alliance procurement, resulting in 45 selected companies and 60 selected products.
Compared with the lowest purchase price in the Union region in 2018, the proposed price has dropped by an average of 59%; compared with the “4+7” pilot price, the average price has dropped by 25%. This round of procurement is fierce and fierce, and some representatives of enterprises are rushing to stimulate.
The core of centralized drug procurement is undoubtedly the price change. After expanding from the pilot to 25 provinces and the Xinjiang Production and Construction Corps, this recruitment will reflect many new features from price to drug quality standards.
First of all, from the price level, the price of drugs that participated in the recruitment this year is not lower than the lowest. The drug that was considered to be the winning bid for a large price cut was unexpectedly out of the game.
When the “4+7” pilot centralized procurement last year, the price of medicines fell by more than 50%, but compared with the lowest purchase price last year, the average price of the proposed price dropped by 59%; compared with the price of the “4+7” pilot. The average drop was 25%. From the data point of view, it is not surprising that pharmaceutical companies have repeatedly issued exclamations of "do not believe" and "too bad".
After all, the provinces that implement the centralized drug procurement mechanism have expanded significantly, and once the drugs are won, they will have huge sales as a guarantee. Such a huge piece of cake, no pharmaceutical companies do not care.
Second, in addition to price competition, competition for drug quality has gradually escalated.
Quality priority is a principle of centralized drug procurement. If this basic requirement is not met, there will be no qualifications for entering the recruitment site. In the past, when drugs were recruited, legally listed generic drugs could participate, but today, only generic drugs that have been evaluated for consistency in efficacy have the qualification to participate in centralized drug procurement.
It should also be noted that when the centralized procurement last year, there was only one company for each type of winning bid, and the company could breathe a sigh of relief after winning the bid. However, this year, the new rules for “multiple bids” have been introduced. The pharmaceutical companies still can't sit still and still need to compete in quality competition among many successful bidders. Pharmaceutical companies must always be vigilant to ensure that prices continue to fall and quality continues to rise. Invincible, continue to win the market.
Compared with the boring atmosphere of the drug recruitment site in the early years ago, today's drug recruitment scene can be described as choppy, which is the result of the “small drug procurement” squid effect.
Some people are worried that enterprises can't adapt. This kind of concern can be understood: drug bidding should be rational and appropriate, price and quality should be taken into consideration at the same time, because the profit is too low, the risk of drug supply is broken, and other supporting mechanisms should be taken to prevent the whole The centralized drug procurement model is more scientific and sustainable.
But the market has its own rules and powerful adjustment functions. When the price is too low to affect the survival of the enterprise, the company will find solutions, such as moderate price increases, cost control, and quality improvement. As long as the market supply is sufficient, the price will be reasonable, and the low price concerns given to others are not as good as their own technology upgrades to ensure high quality and low prices, in order to gain competitiveness.
It can be foreseen that the fierce competition for the centralized procurement of medicines must move from the recruitment site to the production line, thus bringing the reshuffle of pharmaceutical companies. Enterprises with insufficient innovation capabilities, poor cost control, and low management efficiency will inevitably be eliminated. The strong players are also competitive and competitive, and will stand out in the fierce competition.
And its positive externalities will also spill over into the realm of people's livelihood: the benign and orderly competition of pharmaceutical enterprises, let the people use low-cost drugs, safe medicine, and benefit the general public.